CVN417 is an orally active antagonist of nAChR containing the α6 subunit, modulating phasic dopaminergic neurotransmission in an impulse-dependent fashion. It inhibits Ca(2+) efflux through nAChR subunits, displaying IC50 values of 0.086 μM (α6), 2.56 μM (α3), and 0.657 μM (α4). CVN417 has shown efficacy in reducing resting tremor in rodent models, suggesting a potential to ameliorate movement disorders in conditions like Parkinson's disease [1].

CVN417（10 μM; 0-2 h）在人类肝微粒和肝细胞展示了较低的代谢周转率[1]。体外ADME数据显示，CVN417在不同物种肝微粒的Cl int（μL/min/mg）值分别为：人2.8，大鼠31.2，小鼠33.3，犬27.7；在肝细胞中的比值（mL/min/10^6 cells）为：人3.7，大鼠20.8，小鼠25.1，犬32.3[1]。